181 related articles for article (PubMed ID: 30890064)
1. Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.
Capetti AF; De Socio GV; Cossu MV; Sterrantino G; Cenderello G; Cattelan A; Baldin GM; Soria A; Riccardi N; Niero FP; Celesia BM; Barbarini G; Rusconi S; Rizzardini G
HIV Clin Trials; 2018 Dec; 19(6):242-248. PubMed ID: 30890064
[TBL] [Abstract][Full Text] [Related]
2. Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
Capetti AF; Sterrantino G; Cossu MV; Cenderello G; Cattelan AM; De Socio GV; Rusconi S; Riccardi N; Baldin GM; Cima S; Niero FP; Rizzardini G; Sasset L
Antivir Ther; 2017; 22(3):257-262. PubMed ID: 27661787
[TBL] [Abstract][Full Text] [Related]
3. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
Capetti AF; Cossu MV; Orofino G; Sterrantino G; Cenderello G; De Socio GV; Cattelan AM; Soria A; Rusconi S; Riccardi N; Baldin GM; Niero FP; Barbarini G; Rizzardini G
BMC Infect Dis; 2017 Sep; 17(1):658. PubMed ID: 28964268
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
[TBL] [Abstract][Full Text] [Related]
5. Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals.
Hawkins KL; Montague BT; Rowan SE; Beum R; McLees MP; Johnson S; Gardner EM
Antivir Ther; 2019; 24(7):513-519. PubMed ID: 31538963
[TBL] [Abstract][Full Text] [Related]
6. Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV.
Lee YL; Lin KY; Cheng SH; Lu PL; Wang NC; Ho MW; Yang CJ; Liou BH; Tang HJ; Huang SS; Huang SH; Chen TC; Lin CY; Lin SP; Lee YT; Hung CC;
Int J Antimicrob Agents; 2021 Sep; 58(3):106403. PubMed ID: 34289404
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients.
Vizcarra P; Fontecha M; Monsalvo M; Vivancos MJ; Rojo A; Casado JL
Antivir Ther; 2019; 24(6):467-471. PubMed ID: 31172977
[TBL] [Abstract][Full Text] [Related]
8. Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
Jabłonowska E; Siwak E; Bociąga-Jasik M; Gąsiorowski J; Kalinowska A; Firląg Burkacka E; Wójcik-Cichy K; Piątek A; Cielniak I; Horban A
PLoS One; 2019; 14(1):e0210476. PubMed ID: 30653541
[TBL] [Abstract][Full Text] [Related]
9. Dolutegravir with boosted darunavir as treatment simplification for treatment-experienced HIV patients with multiple mutations.
Paparizos V; Vasalou V; Kourkounti S
Int J STD AIDS; 2019 Oct; 30(12):1214-1215. PubMed ID: 31775586
[No Abstract] [Full Text] [Related]
10. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Casado JL;
Infect Dis (Lond); 2020 Mar; 52(3):202-206. PubMed ID: 31760833
[No Abstract] [Full Text] [Related]
11. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
[TBL] [Abstract][Full Text] [Related]
12. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
Akil B; Blick G; Hagins DP; Ramgopal MN; Richmond GJ; Samuel RM; Givens N; Vavro C; Song IH; Wynne B; Ait-Khaled M;
Antivir Ther; 2015; 20(3):343-8. PubMed ID: 25321146
[TBL] [Abstract][Full Text] [Related]
14. Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort.
Capetti AF; Sterrantino G; Cossu MV; Orofino G; Barbarini G; De Socio GV; Di Giambenedetto S; Di Biagio A; Celesia BM; Argenteri B; Rizzardini G
PLoS One; 2016; 11(10):e0164753. PubMed ID: 27741309
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir with boosted darunavir treatment simplification for the transmitted HIV thymidine analog resistance in Manitoba, Canada.
Wheeler J; Chan S; Harrigan PR; Becker M; Kasper K; Keynan Y
Int J STD AIDS; 2018 Apr; 29(5):520-522. PubMed ID: 29513131
[No Abstract] [Full Text] [Related]
16. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
17. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.
Todd S; Rafferty P; Walker E; Hunter M; Dinsmore WW; Donnelly CM; McCarty EJ; Quah SP; Emerson CR
Int J STD AIDS; 2017 Oct; 28(11):1074-1081. PubMed ID: 28118801
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results.
Oldenbuettel C; Wolf E; Ritter A; Noe S; Heldwein S; Pascucci R; Wiese C; Von Krosigk A; Jaegel-Guedes E; Jaeger H; Balogh A; Koegl C; Spinner CD
Antivir Ther; 2017; 22(2):169-172. PubMed ID: 27588613
[TBL] [Abstract][Full Text] [Related]
19. Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance.
Wolf E; Boesecke C; Balogh A; Bidner H; Cordes C; Heiken H; Krznaric I; Kümmerle T; Stellbrink HJ; Schneider J; Spinner CD;
AIDS Res Ther; 2021 Sep; 18(1):58. PubMed ID: 34496848
[TBL] [Abstract][Full Text] [Related]
20. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]